open access

Vol 88, No 6 (2020)
Research paper
Submitted: 2020-04-28
Accepted: 2020-07-20
Published online: 2020-12-16
Get Citation

Bronchodilatory effects of B-type natriuretic peptide in acute asthma attacks: a randomized controlled clinical trial

Hassan Motamed1, Arash Forouzan12, Habib Heybar3, Mohammad Javad Khorasani1, Saeed Hesam4
DOI: 10.5603/ARM.a2020.0178
·
Pubmed: 33393645
·
Adv Respir Med 2020;88(6):531-538.
Affiliations
  1. Emergency Medicine Department, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  2. Air Pollution and Respiratory Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  3. Cardiology Department, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  4. Biostatistics Department, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Khouzestan, Iran

open access

Vol 88, No 6 (2020)
ORIGINAL PAPERS
Submitted: 2020-04-28
Accepted: 2020-07-20
Published online: 2020-12-16

Abstract

Introduction: B-type natriuretic peptide (BNP) regulates different physiological processes such as blood pressure, cardiac growth, and neural and skeletal development. Thus, the aim of this study w as to evaluate the effect of BNP in the treatment of acute asthma attacks.
Material and methods: In this randomized clinical trial, patients with acute asthma attacks were enrolled. The patients were divided randomly into two groups. Patients in the interventional group received BNP via intravenous infusion. Two µg/kg of BNP was injected as a bolus in 60 seconds. Then, infusion of BNP immediately began and was given in 0.01, 0.02, and 0.03 µg/kg/min doses every 30 minutes for the first 1.5 hours. The patients in the control group received nebulized salbutamol. Afterwards, peak flow meter findings, hemodynamic parameters, and estimation of the clinical severity of asthma in both groups were checked every 30 minutes. Results: In total, 40 patients were included in this study. The values of PEFR in the 60th and 90th minutes in the control group were lower than those in the interventional group. In the 60th minute, the mean of PEFR was 377.3 in the BNP group but 335.95 in the control group (P = 0.049). Moreover, this difference remained significant in the 90th minute (P = 0.021). However, forced expiratory volume in one second (FEV1) did not differ between the groups at any time (p > 0.05).
Conclusion: Although a large experimental study is needed to verify our hypothesis, it seems that BNP might be a therapeutic option in asthma exacerbations, particularly in those with b2 agonist receptor polymorphism.

Abstract

Introduction: B-type natriuretic peptide (BNP) regulates different physiological processes such as blood pressure, cardiac growth, and neural and skeletal development. Thus, the aim of this study w as to evaluate the effect of BNP in the treatment of acute asthma attacks.
Material and methods: In this randomized clinical trial, patients with acute asthma attacks were enrolled. The patients were divided randomly into two groups. Patients in the interventional group received BNP via intravenous infusion. Two µg/kg of BNP was injected as a bolus in 60 seconds. Then, infusion of BNP immediately began and was given in 0.01, 0.02, and 0.03 µg/kg/min doses every 30 minutes for the first 1.5 hours. The patients in the control group received nebulized salbutamol. Afterwards, peak flow meter findings, hemodynamic parameters, and estimation of the clinical severity of asthma in both groups were checked every 30 minutes. Results: In total, 40 patients were included in this study. The values of PEFR in the 60th and 90th minutes in the control group were lower than those in the interventional group. In the 60th minute, the mean of PEFR was 377.3 in the BNP group but 335.95 in the control group (P = 0.049). Moreover, this difference remained significant in the 90th minute (P = 0.021). However, forced expiratory volume in one second (FEV1) did not differ between the groups at any time (p > 0.05).
Conclusion: Although a large experimental study is needed to verify our hypothesis, it seems that BNP might be a therapeutic option in asthma exacerbations, particularly in those with b2 agonist receptor polymorphism.

Get Citation

Keywords

bronchodilator agents; asthma, B-type natriuretic peptide; emergency medicine

About this article
Title

Bronchodilatory effects of B-type natriuretic peptide in acute asthma attacks: a randomized controlled clinical trial

Journal

Advances in Respiratory Medicine

Issue

Vol 88, No 6 (2020)

Article type

Research paper

Pages

531-538

Published online

2020-12-16

DOI

10.5603/ARM.a2020.0178

Pubmed

33393645

Bibliographic record

Adv Respir Med 2020;88(6):531-538.

Keywords

bronchodilator agents
asthma
B-type natriuretic peptide
emergency medicine

Authors

Hassan Motamed
Arash Forouzan
Habib Heybar
Mohammad Javad Khorasani
Saeed Hesam

References (30)
  1. American Lung Association Epidemiology and Statistics Unit, Research and Program Services Division 2012.
  2. National Asthma Education and Prevention Program. Third Expert Panel on the Diagnosis and Management of Asthma. Expert panel report 3: guidelines for the diagnosis and management of asthma. Bethesda: National Heart, Lung, and Blood Institute. 2007.
  3. Ivanova JI, Bergman R, Birnbaum HG, et al. Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. J Allergy Clin Immunol. 2012; 129(5): 1229–1235.
  4. National Heart, Lung and Blood Institute. Global Initiative for asthma. Global strategy for asthma management and prevention. NHLBI/WHO workshop report. Bethesda, Md: NIH. 2002.
  5. National Institutes of Health and National Heart, Lung, and Blood Institute. Guidelines for the diagnosis and management of asthma–update on selected topics 2002. Washington, DC: US Dept of Health and Human Services. 2002.
  6. National Asthma Council. Asthma Management Handbook 2002. National Asthma Council Australia, Ltd, Melbourne 2002.
  7. British Thoracic Society. Scottish Intercollegiate Guidelines Network British Guideline on the Management of Asthma. Thorax. 2003; 58(Suppl 1): i1–94.
  8. Becker A, Lemière C, Bérubé D, et al. Summary of recommendations from the Canadian Asthma Consensus guidelines, 2003. CMAJ. 2005; 173(6 Suppl): S3–11.
  9. Kercsmar CM, McDowell KM. Love it or lev it: levalbuterol for severe acute asthma--for now, leave it. J Pediatr. 2009; 155(2): 162–164.
  10. Fischl MA, Pitchenik A, Gardner LB. An index predicting relapse and need for hospitalization in patients with acute bronchial asthma. N Engl J Med. 1981; 305(14): 783–789.
  11. Hall IP. Pharmacogenetics of asthma. Eur Respir J. 2000; 15: 449–451.
  12. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull. 2000; 56(4): 1054–1070.
  13. Palmer LJ, Silverman ES, Weiss ST, et al. Pharmacogenetics of asthma. Am J Respir Crit Care Med. 2002; 165(7): 861–866.
  14. Koga T, Kamimura T, Oshita Y, et al. Determinants of bronchodilator responsiveness in patients with controlled asthma. J Asthma. 2006; 43(1): 71–74.
  15. Tsai HJ, Shaikh N, Kho JY, et al. Beta 2-adrenergic receptor polymorphisms: pharmacogenetic response to bronchodilator among African American asthmatics. Hum Genet. 2006; 119(5): 547–557.
  16. Tantisira KG, Hwang ES, Raby BA, et al. TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci U S A. 2004; 101(52): 18099–18104.
  17. Tantisira KG, Lake S, Silverman ES, et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet. 2004; 13(13): 1353–1359.
  18. Tantisira KG, Silverman ES, Mariani TJ, et al. FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma. J Allergy Clin Immunol. 2007; 120(6): 1285–1291.
  19. Pandey KN, Pandey KN. Stoichiometric analysis of internalization, recycling, and redistribution of photoaffinity-labeled guanylate cyclase/atrial natriuretic factor receptors in cultured murine Leydig tumor cells. J Biol Chem. 1993; 268(6): 4382–4390.
  20. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev. 2006; 27(1): 47–72.
  21. Potter LR, Yoder AR, Flora DR, et al. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol. 2009(191): 341–366.
  22. Hellermann G, Kong X, Gunnarsdóttir J, et al. Mechanism of bronchoprotective effects of a novel natriuretic hormone peptide. J Allergy Clin Immunol. 2004; 113(1): 79–85.
  23. Bianchi C, Gutkowska J, Thibault G, et al. Radioautographic localization of 125I-atrial natriuretic factor (ANF) in rat tissues. Histochemistry. 1985; 82(5): 441–452.
  24. Kawaguchi S, Uchida K, Ito T, et al. Immunohistochemical localization of atrial natriuretic peptide receptor in bovine kidney and lung. J Histochem Cytochem. 1989; 37(11): 1739–1742.
  25. Matera MG, Calzetta L, Passeri D, et al. Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi. Br J Pharmacol. 2011; 163(8): 1740–1754.
  26. Calzetta L, Passeri D, Kanabar V, et al. Brain natriuretic peptide protects against hyperresponsiveness of human asthmatic airway smooth muscle via an epithelial cell-dependent mechanism. Am J Respir Cell Mol Biol. 2014; 50(3): 493–501.
  27. Akerman MJ, Yaegashi M, Khiangte Z, et al. Bronchodilator effect of infused B-type natriuretic peptide in asthma. Chest. 2006; 130(1): 66–72.
  28. Orlandi A, Calzetta L, Doldo E, et al. Brain natriuretic peptide modulates calcium homeostasis and epidermal growth factor receptor gene signalling in asthmatic airways smooth muscle cells. Pulm Pharmacol Ther. 2015; 31: 51–54.
  29. Matera MG, Calzetta L, Parascandolo V, et al. Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi. Pulm Pharmacol Ther. 2009; 22(6): 478–482.
  30. Nishimura K, Nishimura T, Onishi K, et al. Changes in plasma levels of B-type natriuretic peptide with acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2014; 9: 155–162.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl